Safety and Efficacy of Fingolimod in MS Patients in China

NCT01941004 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis (Relapsing Remitting)

Interventions

DRUG: fingolimod
DRUG: Placebo (6mos) + open label fingolimod (6 mos)

Sponsor

Novartis Pharmaceuticals